X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (231799) 231799
Newsletter (6051) 6051
Newspaper Article (856) 856
Book Chapter (500) 500
Magazine Article (268) 268
Book / eBook (185) 185
Dissertation (97) 97
Conference Proceeding (34) 34
Trade Publication Article (30) 30
Publication (24) 24
Journal / eJournal (18) 18
Web Resource (10) 10
Transcript (8) 8
Book Review (7) 7
Streaming Video (6) 6
Government Document (5) 5
Reference (4) 4
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (180148) 180148
female (97988) 97988
oncology (94643) 94643
male (81542) 81542
cancer (77133) 77133
middle aged (72440) 72440
aged (62576) 62576
adult (49597) 49597
carcinoma (48726) 48726
animals (44893) 44893
chemotherapy (43782) 43782
cell line, tumor (30611) 30611
care and treatment (30442) 30442
tumors (29151) 29151
treatment outcome (28880) 28880
prognosis (28740) 28740
mice (28479) 28479
apoptosis (28312) 28312
research (27555) 27555
metastasis (27267) 27267
lung neoplasms - drug therapy (26764) 26764
antineoplastic combined chemotherapy protocols - therapeutic use (26693) 26693
expression (26360) 26360
antineoplastic agents - therapeutic use (23458) 23458
aged, 80 and over (21582) 21582
analysis (20419) 20419
survival (20367) 20367
therapy (20360) 20360
surgery (19196) 19196
carcinoma, non-small-cell lung - drug therapy (19184) 19184
health aspects (19150) 19150
neoplasm staging (18931) 18931
cancer therapies (16123) 16123
proteins (15754) 15754
combined modality therapy (15698) 15698
gene expression (15479) 15479
retrospective studies (15404) 15404
pharmacology & pharmacy (15133) 15133
squamous cell carcinoma (15107) 15107
hepatocellular carcinoma (14961) 14961
antineoplastic agents - pharmacology (14856) 14856
radiotherapy (14666) 14666
lung cancer (14408) 14408
medicine & public health (14373) 14373
cisplatin (14357) 14357
lung neoplasms - pathology (14307) 14307
carcinoma, squamous cell - drug therapy (14285) 14285
drug therapy (13808) 13808
breast cancer (13703) 13703
hepatocellular-carcinoma (13432) 13432
cell biology (13193) 13193
patients (12936) 12936
apoptosis - drug effects (12845) 12845
genetic aspects (12842) 12842
survival rate (12292) 12292
development and progression (12183) 12183
survival analysis (11916) 11916
immunohistochemistry (11812) 11812
risk factors (11777) 11777
medical prognosis (11684) 11684
liver cancer (11561) 11561
biochemistry & molecular biology (11386) 11386
cisplatin - administration & dosage (11381) 11381
mutation (11184) 11184
kinases (11032) 11032
cell proliferation - drug effects (11014) 11014
disease-free survival (11000) 11000
gastroenterology & hepatology (10822) 10822
medicine (10822) 10822
growth (10756) 10756
follow-up studies (10599) 10599
carcinoma, non-small-cell lung - pathology (10192) 10192
squamous-cell carcinoma (10188) 10188
breast-cancer (10106) 10106
liver neoplasms - drug therapy (10090) 10090
metastases (10069) 10069
mice, nude (10052) 10052
medicine, research & experimental (10026) 10026
cell proliferation (9833) 9833
signal transduction (9791) 9791
research article (9700) 9700
time factors (9581) 9581
carcinoma, squamous cell - pathology (9481) 9481
studies (9473) 9473
hematology, oncology and palliative medicine (9314) 9314
immunotherapy (9269) 9269
dose-response relationship, drug (9255) 9255
diagnosis (9190) 9190
gene expression regulation, neoplastic (9143) 9143
angiogenesis (9098) 9098
tumor cells, cultured (9029) 9029
colorectal cancer (8980) 8980
activation (8957) 8957
carcinoma, hepatocellular - drug therapy (8785) 8785
antineoplastic agents - administration & dosage (8747) 8747
liver neoplasms - pathology (8739) 8739
medical research (8692) 8692
cells (8680) 8680
cell cycle (8645) 8645
oncology, experimental (8606) 8606
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (69) 69
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (27) 27
Collection Dvlpm't (Acquisitions) - Vendor file (17) 17
Online Resources - Online (14) 14
Gerstein Science - Periodical Stacks (6) 6
Collection Dvlpm't (Acquisitions) - Closed Orders (4) 4
UofT at Mississauga - Stacks (4) 4
Lakeridge Health Sciences - Oshawa (3) 3
St. Michael's Hospital - Stacks (3) 3
Gerstein Science - Reference (2) 2
Markham Stouffville Hospital - Stacks (2) 2
New College (Ivey) - Stacks (2) 2
Scarborough Hospital - Birchmount (2) 2
Women's College Hospital - Stacks (2) 2
Baycrest Hospital - Wellness Library (1) 1
Earth Sciences (Noranda) - Stacks (1) 1
Gerstein Science - Bindery (1) 1
Gerstein Science - Circulation Desk (1) 1
Humber River Regional Hospital - Church Stacks (1) 1
Humber River Regional Hospital - Finch Stacks (1) 1
Mathematical Sciences - Stacks (1) 1
Providence Healthcare - Stacks (1) 1
Richard Charles Lee Canada-Hong Kong - Library use only (1) 1
Scarborough Hospital - General (1) 1
St Josephs Health Centre - Stacks (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
Sunnybrook Health Sciences Centre - Online (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Periodicals (1) 1
UTL at Downsview - May be requested (1) 1
University College (Laidlaw) - Stacks (1) 1
UofT Schools - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (229431) 229431
Japanese (4113) 4113
German (2496) 2496
French (2158) 2158
Chinese (1822) 1822
Russian (878) 878
Spanish (595) 595
Italian (452) 452
Polish (296) 296
Hungarian (138) 138
Korean (111) 111
Portuguese (106) 106
Czech (93) 93
Dutch (83) 83
Danish (61) 61
Bulgarian (49) 49
Ukrainian (43) 43
Romanian (34) 34
Hebrew (24) 24
Serbian (22) 22
Norwegian (20) 20
Swedish (20) 20
Turkish (20) 20
Croatian (17) 17
Finnish (14) 14
Arabic (11) 11
Lithuanian (11) 11
Slovak (11) 11
Bosnian (3) 3
Slovenian (3) 3
Greek (2) 2
Afrikaans (1) 1
Icelandic (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Molecular cancer therapeutics, ISSN 1535-7163, 2001
Journal
Cancer Treatment Reviews, ISSN 0305-7372, 2016, Volume 44, pp. 51 - 60
Highlights • Role of immune checkpoint inhibition in the management of key malignancies. • Description of rates of immune-related adverse events and timing of... 
Hematology, Oncology and Palliative Medicine | Pembrolizumab | Immune-related adverse events | Renal cancer | Ipilimumab | Nivolumab | Lung cancer | Melanoma | Immune-checkpoint inhibitors | OPEN-LABEL | SINGLE-ARM | ANTI-CTLA-4 ANTIBODY | METASTATIC MELANOMA | ONCOLOGY | ADVANCED MELANOMA | LONG-TERM SAFETY | MALIGNANT MESOTHELIOMA | ENTERIC NEUROPATHY | ADVERSE EVENTS | IPILIMUMAB RETREATMENT | Lung Neoplasms - drug therapy | Skin Neoplasms - drug therapy | Humans | Immunosuppressive Agents - therapeutic use | Antibodies, Monoclonal - adverse effects | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Adrenal Cortex Hormones - therapeutic use | Diarrhea - chemically induced | Infliximab - therapeutic use | Drug Eruptions - drug therapy | Antineoplastic Agents - adverse effects | Colitis - chemically induced | Antilymphocyte Serum - therapeutic use | Colitis - drug therapy | Carcinoma, Renal Cell - drug therapy | Chemical and Drug Induced Liver Injury - etiology | Pituitary Diseases - chemically induced | Pituitary Diseases - drug therapy | Antibodies, Monoclonal, Humanized - adverse effects | Drug Eruptions - etiology | Neoplasms - drug therapy | Cyclosporine - therapeutic use | Tacrolimus - therapeutic use | Mycophenolic Acid - analogs & derivatives | Mycophenolic Acid - therapeutic use | Melanoma - drug therapy | Chemical and Drug Induced Liver Injury - drug therapy | Diarrhea - drug therapy | CTLA-4 Antigen - antagonists & inhibitors | Kidney Neoplasms - drug therapy | Thyroiditis - drug therapy | Thyroiditis - chemically induced | Index Medicus
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2014, Volume 135, Issue 2, pp. 223 - 230
Abstract Objectives Complete surgery with no macroscopic residual disease (RD) at primary (PDS) or interval debulking surgery (IDS) is the main objective of... 
Hematology, Oncology and Palliative Medicine | Obstetrics and Gynecology | Neoadjuvant chemotherapy | Number of cycles | Interval surgery | Prognosis | Epithelial ovarian cancer | Number of cycles Prognosis | SURVIVAL | TRIALS | CYTOREDUCTIVE SURGERY | METAANALYSIS | SENSITIVITY | RESIDUAL DISEASE | OBSTETRICS & GYNECOLOGY | ONCOLOGY | ADVANCED-STAGE OVARIAN | RESISTANCE | PRIMARY DEBULKING SURGERY | CARCINOMA | Adenocarcinoma - pathology | Adenocarcinoma, Mucinous - pathology | Carcinosarcoma - surgery | Humans | Middle Aged | Ovarian Neoplasms - pathology | Cystadenocarcinoma, Serous - pathology | Cystadenocarcinoma, Serous - drug therapy | Cytoreduction Surgical Procedures | Young Adult | Carcinoma, Endometrioid - surgery | Adenocarcinoma, Mucinous - surgery | Aged, 80 and over | Adult | Female | Neoadjuvant Therapy | Retrospective Studies | Adenocarcinoma, Mucinous - drug therapy | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Adenocarcinoma, Clear Cell - surgery | Carcinosarcoma - pathology | Neoplasms, Glandular and Epithelial - pathology | Reoperation | Treatment Outcome | Carcinoma, Endometrioid - drug therapy | Adenocarcinoma - drug therapy | Cystadenocarcinoma, Serous - surgery | Neoplasms, Glandular and Epithelial - surgery | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Adenocarcinoma, Clear Cell - pathology | Aged | Carcinosarcoma - drug therapy | Platinum Compounds - administration & dosage | Carcinoma, Endometrioid - pathology | Adenocarcinoma - surgery | Adenocarcinoma, Clear Cell - drug therapy | Cohort Studies | Ovarian Neoplasms - surgery | Cancer patients | Care and treatment | Surgery | Adjuvant treatment | Ovarian cancer | Cancer | Life Sciences
Journal Article
Anti-cancer drugs, ISSN 0959-4973, 1990
Journal
Cancer chemotherapy and pharmacology, ISSN 0344-5704, 1978
Journal
The New England journal of medicine, ISSN 1533-4406, 2012, Volume 366, Issue 26, pp. 2455 - 2465
Antibodies to PD-1 protein and to one of its ligands, PD-L1, have shown antitumor activity. Unleashing T cells from inhibitory signals may be a strategy to... 
MEDICINE, GENERAL & INTERNAL | IMMUNOTHERAPY | GUIDELINES | B7 FAMILY | B7-H1 | CTLA-4 | LIGAND | BLOCKADE | CLINICAL ACTIVITY | PHASE-I | PD-1 | Neoplasms - metabolism | Humans | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Pancreatic Neoplasms - drug therapy | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Adult | Female | Carcinoma, Renal Cell - drug therapy | Ovarian Neoplasms - drug therapy | Programmed Cell Death 1 Receptor - metabolism | Stomach Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Neoplasms - drug therapy | Antibodies, Monoclonal - administration & dosage | Melanoma - drug therapy | Nivolumab | Carcinoma, Non-Small-Cell Lung - drug therapy | Programmed Cell Death 1 Receptor - immunology | Intravenous administration | Kidneys | Immune response | Disease | PD-1 protein | Tumor cells | Colorectal carcinoma | Body weight | Melanoma | Lymphocytes T | Breast cancer | Stomach cancer | Patients | Ovarian cancer | Lungs | Pancreatic cancer | PD-L1 protein | Antitumor activity | Ligands | Autoimmune diseases | Gastric cancer | Clear cell-type renal cell carcinoma | Apoptosis | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Journal of experimental therapeutics & oncology, ISSN 1359-4117, 1996
Journal
Cancer, ISSN 0008-543X, 2017, Volume 123, Issue 11, pp. 1904 - 1911
.... To address this challenge, this review aggregates and synthesizes the available preclinical and clinical data surrounding immune checkpoint inhibitor therapy in challenging clinical... 
pembrolizumab | autoimmune | nivolumab | elderly | ipilimumab | pediatrics | pregnancy | transplant | organ dysfunction | ALLOGRAFT-REJECTION | PERFORMANCE STATUS | PD-1 BLOCKADE | OPEN-LABEL | CELL LUNG-CANCER | IPILIMUMAB THERAPY | ONCOLOGY | ADVANCED MELANOMA | BRAIN METASTASES | AUTOIMMUNE-DISEASE | T-CELLS | Lung Neoplasms - drug therapy | Melanoma - complications | Age Factors | Humans | Immunosuppressive Agents - therapeutic use | Ipilimumab | Antibodies, Monoclonal - therapeutic use | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Hepatitis C, Chronic - complications | Transplant Recipients | Neoplasms - complications | Brain Neoplasms - secondary | Squamous Cell Carcinoma of Head and Neck | Pregnancy Complications, Neoplastic - drug therapy | Female | Carcinoma, Renal Cell - drug therapy | Kidney Neoplasms - complications | Graft Rejection - prevention & control | Autoimmune Diseases - complications | Head and Neck Neoplasms - drug therapy | Brain Neoplasms - drug therapy | Lung Neoplasms - complications | Neoplasms - drug therapy | Pregnancy | Carcinoma, Non-Small-Cell Lung - complications | B7-H1 Antigen - antagonists & inhibitors | Carcinoma, Squamous Cell - drug therapy | Hepatitis B, Chronic - complications | Carcinoma, Squamous Cell - complications | Melanoma - drug therapy | Nivolumab | HIV Infections - complications | Head and Neck Neoplasms - complications | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Renal Cell - complications | Immunocompromised Host | CTLA-4 Antigen - antagonists & inhibitors | Kidney Neoplasms - drug therapy | Virus diseases | Care and treatment | Dosage and administration | Research | Cell death | Immunosuppressive agents | Medical research | Brain | Populations | Toxicity | Decision making | Mortality | Disorders | Clinical trials | Cytotoxicity | Lymphocytes T | Metastasis | Patients | Regulatory approval | Metastases | Inhibitors | Immune checkpoint | Aggregates | Lymphocytes | Safety | Autoimmune diseases | Cancer | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2012, Volume 366, Issue 26, pp. 2443 - 2454
Releasing T cells from inhibitory control has been a strategy exploited by the anti–CTLA-4 antibody ipilimumab. Now an antibody against a second checkpoint... 
CRITERIA | MEDICINE, GENERAL & INTERNAL | THERAPY | IMMUNOTHERAPY | GUIDELINES | B7 FAMILY | B7-H1 | MEMBER | Neoplasms - metabolism | Antibodies, Monoclonal - pharmacology | Humans | Antibodies, Monoclonal - adverse effects | Programmed Cell Death 1 Receptor - metabolism | Antibodies, Monoclonal - therapeutic use | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Neoplasms - drug therapy | Dose-Response Relationship, Drug | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Melanoma - drug therapy | Adult | Female | Ligands | Antineoplastic Agents - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Programmed Cell Death 1 Receptor - immunology | Carcinoma, Renal Cell - drug therapy | Prostatic Neoplasms - drug therapy | Drugs | Dose-response relationship (Biochemistry) | Immune response | Anti-antibodies | Dosage and administration | Product/Service Evaluations | Regulation | Research | Drug therapy | Cancer | Fees & charges | Kidneys | Stock options | PD-1 protein | Laboratories | Toxicity | Tumor cells | Body weight | Lung cancer | Colorectal carcinoma | Colorectal cancer | Melanoma | Licenses | Lymphocytes T | Patients | Castration | PD-L1 protein | Antitumor activity | Prostate cancer | Drug dosages | Prostate | Clear cell-type renal cell carcinoma | Tumors | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article